Comorbidities in Iranian Obese Psoriatic Patients Compared With Non-Obese Patients

  • Omid Zargari Mail Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Seyyede Zeinab Azimi ORCID Department of Dermatology, Skin Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  • Tara Barat Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Vahide Lajevardi Department of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Ehsan Kazemnezhad Department of Biostatistics, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Mohammad Shahidi Dadras Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Psoriasis, Obesity, Metabolic syndrome, Comorbidity


Psoriasis is a common chronic inflammatory skin disease, which is gradually being recognized as a systemic inflammatory disorder. Psoriasis and obesity are strongly linked, but there is not enough data whether obese psoriatic patients present differently from non-obese psoriatic patients. To compare the phenotype, clinical features, severity, baseline comorbidities and laboratory findings among psoriatic patients with/without obesity all the psoriatic patients, from three centers, who were receiving systemic therapy were included in the study. Patients were divided into two groups: those with obesity and those without obesity. We included 497 patients: 154 (31%) patients were obese and 343 (69%) were non-obese. Obese patients had more comorbidities, particularly hyperlipidemia, followed by hypertension and diabetes. Fasting blood sugar and serum lipids were significantly higher among obese subjects. Given the differences between obese patients and non-obese patients, the former group should be followed and managed more closely and with specific attention..


Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314–320

Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58(6):1031-42.

Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011; 147(4):419-24

Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systemic review and meta-analysis of observational studies. Nutr Diabetes. 2012; 2:e54

Coimbra S, Catarino C, Santos-Silva A. The triad psoriasis-obesity-adipokine profile. J Eur Acad Dermatol Venereol. 2016; 30(11):1876-1885.

Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes. 2009; 33:151–156

Baran A, Flisiak I, Jaroszewicz J, Świderska M. Effect of psoriasis activity on serum adiponectin and leptin levels. Postep Derm Alergol. 2015; 32:101–6

Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54:1847–56

Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012; 13:707–712

Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527–1534.

Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61–67.

Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143:1559–1565.

Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55: 829–835.

Rahmani A, Sayehmiri K, Asadollahi K, Sarokhani D, Islami F, Sarokhani M.

Investigation of the Prevalence of Obesity in Iran: a Systematic Review and Meta-Analysis Study. Acta Med Iran. 2015 ;53(10):596-607

Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 2010; 57: 143–144.

Warnecke C, Manousaridis I, Herr R, Terris DD, Goebeler M, Goerdt S et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case-control study. Eur J Dermatol 2011; 21: 761–770.

Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167:1670-1675.

Kumar S, Han J, Li T, et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013;27:1293-1298.

Zhang C, Zhu KJ, Zheng HF, Cui Y, et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital-based study. J Eur Acad Dermatol Venereol. 2011;25(1):87-91.

Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895–902.

Florin V, Cottencin AC, Delaporte E, Staumont-Salle D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol; 2013; 27(2):e186-90.

Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 2011; 24: 446–451.

Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 2009; 25: 2311–2316.

Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290–295.

Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341–344.

Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010;63:571‐579.

Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate‐to‐severe chronic plaque psoriasis to low‐dose cyclosporine therapy: a randomized, controlled, investigator‐blinded clinical trial. Am J Clin Nutr 2008;88:1242‐1247.

Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296(14):1735-41

Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010;130:962-967.

Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol. 2013;133: 2347-2354.

Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015;135: 2189-2197.

Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433-442.

Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161:1-7.

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84-91.

Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149: 1173-1179.

Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 pt 1):556-562.

Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and the likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012; 148:995-1000.

Ma C, Harskamp CT, Armstrong EJ, et al. The association between psoriasis and dyslipidemia: a systematic review. Br J Dermatol. 2013;168:486-495.

Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224:218-221.

Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53:1618-1624.

Gul U, Gonul M, Kaya I, Aslan E. Autoimmune thyroid disorders in patients with psoriasis. Eur J Dermatol. 2009;19(3):221-3

Antonelli A, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol. 2006;33(10):2026-8.

James SM, Hill DE, Feldman SR. Hypothyroidism in Patients with Psoriasis or Rosacea: A Large Population Study. Dermatol Online J. 2016; 22 (10).

How to Cite
Zargari O, Azimi SZ, Barat T, Lajevardi V, Kazemnezhad E, Shahidi Dadras M. Comorbidities in Iranian Obese Psoriatic Patients Compared With Non-Obese Patients. Acta Med Iran. 57(4).